Behrman Capital agrees Emmes sale to New Mountain Capital after three-year hold

Mid-market buyout firm Behrman Capital has sealed an exit of clinical research organisation Emmes to buyout major New Mountain Capital. Emmes aims to provide clients including biopharmaceutical companies, government agencies, foundations, academic institutions and other non-profit organizations with the technologies and service required to manage clinical research studies. Never miss a story – click to sign …